Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of cool breezes and clear, blue skies hovering over the Pharmalot campus. This calls for a celebration with a cup of stimulation, which we are managing to brew despite the mischievous official mascot, who likes to steal items from under our nose. And we have also gathered a few items of interest to help you on your journey today. We hope it is a successful one and you conquer the world. Meanwhile, do keep in touch….
Former Food and Drug Administration Commissioner Stephen Hahn is joining Flagship Pioneering, the venture capital firm that launched Moderna (MRNA) and remains closely tied to the vaccine maker, The Washington Post writes. Hahn will serve as a chief medical officer. His move is the latest by a federal official to a company that is regulated by the government or that might profit from firms regulated by the government — what critics call a revolving door that they say undermines trust in federal decisions.
AstraZeneca (AZN) reported a late-stage trial failed to provide evidence its antibody therapy prevented symptomatic Covid-19 in people recently exposed to the virus, the latest disappointment in a broader search for reliable post-infection therapies, The Wall Street Journal says. A single dose of the long-acting antibody was not statistically more effective than a placebo in a trial of 1,121 people. The drug maker received U.S. government support potentially exceeding $700 million for development and to potentially supply hundreds of millions of doses.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Source link
